Role of epigenetics variation with focus on DNA Methylation in triple-negative breast cancer patients

Triple-negative breast cancer (TNBC) is distinguished by the absence of human epidermal growth factor 2 receptors, estrogen, and progesterone. Due to its destructive character and inability to be treated with current endocrine medications, it has one of the worst prognoses of any breast cancer subtype. The only therapies available are chemo-and/or radiation and surgery, which necessitates the development of new biomarkers or therapeutic targets. Due to of their inherent inclination to operate as antisense regulators and interactors of whole gene set implicated in cancer, microRNAs (miRNAs) are a potential target for TNBC-focused therapy. In this paper, we summarize the role of epigenetics variation with a focus on DNA methylation in TNBC patients. Other biomarkers alterations and interactions with miRNAs may lead to the identification of novel therapy options for TNBC in the future as well.